Key facts
- It has raised $35.6M across 1 recorded rounds; the latest was Seed Round ($3.6M) in Jun 2020.
- Notable investors include Polsky Center for Entrepreneurship and Innovation at the University of Chicago, Kennedy Lewis Investment Management, The University of Chicago Office of Investments, InVivium Capital, LYZZ Capital — 7 tracked in total.
- Onchilles Pharma has filed 1 Form D with the SEC, most recently Jul 2020 ($3.6M sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Onchilles Pharma
Funding rounds
1 roundsAbout Onchilles Pharma
Operator of a drug discovery and development company intended to build myeloid-focused cancer therapeutics. The company leverages novel neutrophil and macrophage biology to develop the next generation of immunotherapies, enabling medical professionals to treat cancer patients efficiently.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2017
- Employees
- 9
- Website
- onchillespharma.com/
- Ownership
- Privately Held (backing)
Onchilles Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Onchilles Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Onchilles Pharma in its N-PORT filings yet. We sweep new filings monthly.